The VC firm, Access BridgeGap, will back three to five early-stage therapeutics companies per year.

Len Blavatnik, head of US-based conglomerate Access industries, has committed $75m to a new venture capital (VC) firm looking for deals in US academic laboratories.

The VC firm, Access BridgeGap, will back three to five early-stage therapeutics companies per year.

Blavatnik said: "Access BridgeGap is an important part of Access’ growing interest in life sciences and, specifically, therapeutics.

"Access BridgeGap will pursue the commercialization of academic and entrepreneurial innovations that possess the potential to make a major impact on disease treatment and prevention."

Daniel Behr (pictured), who previously worked at Harvard University’s Office of Technology Development and university spin-out investment firm Allied Minds, is head of the new VC firm, Access BridgeGap Ventures.

Behr, who set up BridgeGap in July, said: "With Access’ support we have the resources and flexibility to span all investment stages and build fully independent companies, either alone or with other investors."

Ben Bronstein, former…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?